Reactome pathway analysis
| Pathway | Adj. P value |
| Group A vs non-OA | |
| EukAryotic translation elongation | 6.2e–63 |
| Extracellular matrix organisation | 7.3e–13 |
| Chemokine receptors bind chemokines | 0.00615 |
| MyD88 deficiency (TLR2/4) | 0.04693 |
| Glycosaminoglycan metabolism | 0.00584 |
| Inflammasomes | 0.01242 |
| Group B vs non-OA | |
| Eukaryotic translation elongation | 1.6e–69 |
| Extracellular matrix organisation | 4.3e–12 |
| Negative regulation of TCF-dependent signalling by WNT ligand antagonists | 0.00707 |
| Regulation of complement cascade | 0.00758 |
| Eicosanoid ligand-binding receptors | 0.00758 |
| Syndecan interactions | 0.01795 |
| Group B vs Group A | |
| Extracellular matrix organisation | 9.2e–11 |
| Chemokine receptors bind chemokines | 8.9e–08 |
| Complement cascade | 0.00012 |
| G alpha (i) signalling events | 0.00036 |
| Adaptive immune system | 0.00068 |
A selection of highly significant differentially regulated Reactome pathways between OA Group A (n=32) and Group B (n=26) and non-OA (n=10).
OA, osteoarthritis.